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Abstract
Background: Clinical trial (and other) data from the European Medicines Agency (EMA) offers the best available
opportunity to address the extensive reporting bias in pharmaceutical trial literature. Data are requested via
freedom of information requests, but 5 years on, little is known about how the system is working.
Methods: Case series of 12 requests for regulatory data (clinical study reports and other regulatory data) relating to
29 different compounds. We logged start and end dates for correspondence with and data releases from the EMA,
the need for additional correspondence and appeal of initial negative decisions, and inspected data releases for
redaction. We measured: time from initial request to first substantive response from the EMA, to final decision from
the EMA (in case of appeal), to initial receipt of documents, and to completion of request; number of data
transmission batches generated; number of pages received for each request; average number of pages per batch
over time (for releases in multiple batches); judgment as to whether the request was satisfied.
Results: We found great variability in time to receive an initial decision from the EMA (1 to 13 weeks). Additional
correspondence with the EMA was necessary in 10 of 12 requests. Four of 12 were initially refused but 3 of 4 were
allowed on appeal after 3 to 33 additional weeks. One request was denied despite appeal. Time to final decision
was 1 to 43 weeks. We received data for 11 of 12 requests in 98 batches. While two requests remain outstanding as
at June 2015 the remaining nine requests took a median 43 weeks to completion (range: 17 to 186 weeks). Despite
redaction in 10 of 11 releases (mainly of researcher and participant identifying information), 8 requested were
wholly satisfied.
Conclusions: The EMA is the only regulator in the world that is routinely releasing original clinical trial data, but
release can take considerable time to occur and often only after a lengthy correspondence. Given its importance
for research and significance for transparency we suggest ways in which the process could be made more efficient.
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Background
For those engaged in research synthesis, regulatory data
not traditionally publicly available are a crucial weapon
to avoid or minimize the impact of reporting bias. These
data, typified by clinical study reports ranging from hun-
dreds to thousands of pages, provide a wealth of audit-
able details on clinical trials well beyond the most
extensive journal publications [1].
While calls to address the many problems of reporting
biases go back decades [2], the past 5 years have wit-
nessed notable progress in the range of campaigns [3, 4],
policies [5, 6], statements and structures [7–11] estab-
lished to expand public access to clinical trial data.
Among all the data transparency initiatives, one process
remains unique: that of the European Medicines Agency
(EMA). Since November 2010, the EMA as data holder
has been providing requestors with clinical trial data relat-
ing to compounds on which a decision has been made
under the centralized registration procedure [5].
The EMA has two distinct policies affecting public ac-
cess to clinical trial data in its holdings, one on request
[12, 13] and the second for data in marketing
authorization applications (MAAs) regarding MAAs
submitted on or after 1 January 2015 (with web data re-
lease to start in 2016) [14].
Since 2010, the EMA has released over two million
pages of regulatory data on request [15, 16], mainly to
industry [16]. The number of requests has grown over
time, from 20 requests per month during the first 2 years
to nearly double that in the 6-month period after, but
pages released in this time period decreased from
around 70,000 pages per month to 44,000 [16].
In September 2013, the EMA expanded its ability to
deal with the growing number of requests, dedicating a
full single 12-person team to a new “Access to Docu-
ments Service” (ATD). When the service began in 2010,
five EMA staff who had other job responsibilities unre-
lated to disclosure handled all requests. Following the
reorganization, the new ATD team had 12 full-time em-
ployees (personal communication, Anne-Sophie Henry-
Eude, 17 November 2014). In 2014, the EMA also re-
leased a guide to help requestors [17].
However, as repeated requestors and recipients of data
from the EMA, our experience has been one of increas-
ing delay and complexity.
We report on the details and outcome of 12 requests
for regulatory data made by us to the EMA between
2011 and June 2015.
Methods
Types of requests
We examined all requests we submitted to the EMA be-
tween November 2010 (when the new EMA policy went
into force) and 30 May 2015, regardless of their fate
(acceptance, partial rejection, or complete rejection). We
included all requests for trial data (the text of the trial it-
self with its protocol and amendments, analysis plans
and tables of results – the clinical study report – and
other documents used by regulators related to trials such
as parts of submissions for the MAA based on trials).
We included animal study data. We treated each request
as a separate case, thereby constructing our own case
series of requests.
Following the submission and receipt of a request, the
Agency may additionally seek clarification, such as
which specific data are being requested, and in what pri-
ority. If the EMA decides to grant the request, it will
consult with the marketing authorization holder of the
relevant product prior to release of data. If the EMA re-
jects a request, it allows the requestor 15 working days
to appeal this decision. The EMA may grant certain por-
tions of a request, but reject others (again, allowing
appeal).
We extracted information across two domains: corres-
pondence and data releases.
Extraction of correspondence
We logged all electronic correspondence and linked data
releases to us from the EMA. We recorded the type of
documents requested, the initial date of each request
and the date of initial EMA approval or rejection of each
request.
We extracted and tabulated data on a simple spread-
sheet on the object and date of the initial request and
answer, in what professional capacity we made the re-
quest (academic researcher or journalist), the presence,
count and timelines of appeals and their resolution, and
whether additional correspondence took place including
clarifications, request modifications and prioritization of
releases from a list of EMA holdings.
Extraction of data releases
We recorded the number of pages released and total
number of batches (release of data on a given date) in
which documents were released. Larger requests are typ-
ically split into multiple batches with no single batch ful-
filling the scope of the overarching request.
We extracted the start and finish date of each data re-
lease. For requests ongoing as of 1 June 2015, we used
the most recent data release date prior to this date. We
also recorded presence and type of redactions and omis-
sion of entire sections of clinical study reports.
Analysis
We calculated the length of time from initial request to:
initial decision by the EMA, final decision (in case of ap-
peals), initial receipt of documents, and completion of
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request (or most recent data release, in case of ongoing
requests).
We calculated the number of data transmission
batches our requests generated, the total number of
pages for each request and the average number of pages
per batch over time, for requests that were split into
multiple batches.
Finally, we made a subjective judgment as to whether
our request was satisfied (i.e., what we received matched
what we requested), recorded as either “Yes,” “Mostly,”
or “No.”
We did not seek ethical approval of our research as it
is not research on human subjects.
Results
We made 15 freedom of information requests to the
EMA between January 2011 (the date of our earliest re-
quest) and 1 June 2015 (our cutoff date). Three requests
were excluded from our analysis (two for correspond-
ence unrelated to trial data and one because of submis-
sion only 4 days prior to our cutoff date). One request
was for documents relating to an EMA review of safety
data from a single company on a range of its products
[18]. The remaining 11 requests related to 29 com-
pounds: 18 antibiotics, 2 antivirals, 1 monoclonal anti-
body, 4 vaccines, 1 volume expander, 1 antipsychotic, 1
statin, and 1 antidiabetic (Table 1). Nine of the 12 re-
quests were made in our capacity as academic re-
searchers; 3 were made in our capacity as journalists.
Table 2 shows the great time variability to receive an
initial decision from the EMA (1 to 13 weeks). Ten of
12 requests entailed additional correspondence with the
EMA beyond the initial request, for example to clarify
the scope of the EMA’s holdings for a particular
therapeutic.
After clarification, 4 of the 12 requests were initially
rejected. Reasons included then-active legal proceedings
and confidentiality regarding an ongoing regulatory pro-
cedure. Examples of request, rejection, and appeal letters
can be seen at http://www.bmj.com/tamiflu/ema/. We
appealed in all cases, and received a positive decision for
three of four appeals in 3 to 33 additional weeks. The
time to receive a final decision, therefore, took between
1 and 43 weeks.
In total, the EMA sent us data in response to 11 of 12
requests. The EMA began sending data for half of re-
quests within 9 weeks. However, for the other half, it
took between 15 and 58 weeks before any data were re-
ceived. Two requests were outstanding at our cutoff
date. Of the remaining nine requests, it took a median
43 weeks to between initial request to final receipt of
data (range: 17 to 186 weeks) (Table 2).
There was great variability in the length of released docu-
ments. Clinical study reports ranged from 7315 to 25,453
pages. Releases delivered in batches were divided into no
more than 5 batches before the year 2013, but afterwards
were divided into between 10 and 22 batches. We observed
no relationship between the overall number of pages re-
leased and number of batches but requests since 2013 were
Table 1 Table of 12 included requests in chronological order
Request no. Date of request Compounds Documents requested
1 25 Jan 2011 1 antiviral: oseltamivir 31 CSRs
2 29 Oct 2011 2 vaccines: Pandemrix and Focetria 4 CSRs, regulatory comments, decision records, other material such
as slides, correspondence, records of meetings, follow-up material
3 22 Dec 2011 1 antipsychotic: aripiprazole 3 CSRs
1 statin: atorvastatin
1 antidiabetic: pioglitazone
4 11 Sep 2012 1 antiviral: oseltamivir 38 animal study reports
5 23 Oct 2012 1 antiviral: oseltamivir 3 periodic safety update reports
6 2 Dec 2012 1 antiviral: oseltamivir Specific analysis from ICH CTD module 5
7 25 Feb 2013 17 antibioticsa Multiple sections of CSR from 97 CSRs
8 4 Apr 2014 1 anti-inflammatory: adalimumab 3 CSRs
9 16 Apr 2014 1 antibiotic: bedaquiline 3 CSRs, CHMP minutes and other CHMP documents
10 16 Apr 2014 48 medicines [21] Infringement procedure documents
11 28 May 2014 2 vaccines: Gardasil and Cervarix 43 CSRs
1 antiviral: sofosbuvir
12 8 May 2015 1 volume expander: hydroxyethyl starch Postmarketing data submitted by the manufacturer
aAltargo, Cayston, Colobreathe, Cubicin, Dificlif, Doribax, Invanz, Ketek, Levviax, Tobi Podhaler, Trovan, Trovan IV, Truvel, Truvel IV, Tygacil, Vibativ, Zinforo
CHMP Committee for Medicinal Products for Human Use, CSR Clinical Study Report, CTD Common Technical Document, ICH International Conference on
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
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generally delivered in a greater number of smaller batches.
There was no relationship between the number of batches
and number of clinical study reports. Our first request was
released in 4 batches and contained a total of 16 clinical
study reports (average 6363 pages per batch), whereas our
eighth request for 3 clinical study reports was delivered
across 12 batches (average 1733 pages per batch) (Table 3;
Fig. 1).
Only our first request was released without any redaction.
All others had variable amounts and types of redactions.
Names and other potentially identifying details of re-
searchers and participants (e.g., participant ID number) was
the most common—but inconsistently applied—type of re-
daction. Other details redacted in some cases included pro-
cedures or methods (e.g., histology testing details),
formulation lot numbers, and the ID numbers of other
studies. Some redactions were so extensive that we were
unable to guess what information was redacted. Despite the
redactions, we judged that in 8 of 12 cases the releases
matched our request, 2 cases of partial match, and 2 cases
of no match.
The dataset underlying this analysis is available, in
Microsoft Excel format, as an online supplement (see
Additional File 1).
Discussion
With little exception, the US Food and Drug Administra-
tion treats clinical study reports and other parts of the dos-
sier submitted by sponsors as commercial confidential
information and, therefore, not releasable under the US
Freedom of Information Act. In contrast, the EMA
interprets all documents, including clinical study reports, to
be subject to its “reactive” freedom of information policy
and is the only regulator in the world routinely releasing
such data. However, the agency is dealing with a huge and
growing number of requests [15, 16].
We made our first request to the EMA in January 2011,
2 months after the promulgation of its then new policy.
We requested clinical study reports for inclusion in our
Cochrane review of neuraminidase inhibitors [19]. Four
months later, we reached this goal, receiving 16 unre-
dacted clinical study reports for oseltamivir. These
documents offered a wealth of detail greatly surpassing
any journal-based trial publication. We became quick
advocates of using regulatory data for research synthesis
because of its powerful potential to address reporting bias
in journal publications [20].
However, as time passed we also witnessed considerable
heterogeneity in times and complexity of the request
process while batches tended to become smaller and fulfill-
ment of requests took longer. Whereas in 2011, we received
16 clinical study reports (25,453 pages) across 4 batches in
4 months, a recent request for clinical study reports for an-
other product has so far been delivered across 22 batches
in almost a year, with an average of 289 pages per batch.
The fewer pages per batch imposes an administrative bur-
den on requestors as clinical study reports may be split
across multiple files and multiple batches but must be
manually combined, to create a complete report, necessary
to carry out an assessment. Second, the tight appeal time
(15 working days) imposes a fair and timely evaluation of
whether redactions are reasonable for each batch of
Table 2 Timeline of correspondence milestones
Request no. Documents receivedb Time to initial
decision, weeks









1 16 CSRs 2 N/A 9 17
2 4 CSRs, regulatory comments, decision records, other
material such as slides, correspondence, records of
meetings, follow-up material
4 N/A 22 186
3 8 CSRs 9 N/A 9 33
4 38 animal study reports 4 N/A 3 17
5 3 periodic safety update reports 1 N/A 5 36
6 Specific analysis from ICH CTD module 5 10 43 43 43
7 Multiple sections of CSR from 97 CSRs 13 22 58 112
8 3 CSRs 7 N/A 7 49
9 3 CSRs, CHMP minutes and other CHMP documents 11 N/A 16 49
10 None 3 7 Appeal denied
11a 43 CSRs for 2 vaccines and 1 antiviral 4 7 15 47
12a Postmarketing data submitted by the manufacturer 3 N/A 3 3
arelease still ongoing at cutoff date; bmay include items expected but not received as of cutoff date
CHMP Committee for Medicinal Products for Human Use, CSR Clinical Study Report, CTD Common Technical Document, ICH International Conference on
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, N/A not applicable
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documents. We found this task hard to keep up with. We
suggest keeping a careful and up-to-date request log to
avoid losing data or duplicating the request, both of which
happened to us.
Long data access request and receipt timelines may
provide an obstacle for researchers accustomed to read-
ily accessible journal publications and encourage neglect
of what is as near a “gold standard” of evidence com-
pleteness as is currently possible. Some researchers may
choose to forgo a chance to address reporting bias in
their work and in doing so perpetuate the known prob-
lems in contemporary scientific publications.
A second concern is that the length of the EMA’s
process may lead some to argue against the EMA’s ap-
proach itself and in favor of other data access initiatives
such as ClinicalStudyDataRequest.com, a joint initiative of
12 pharmaceutical companies. While we support all ef-
forts in this area, the EMA’s approach remains unique,
and is based on the view that it is the regulator’s duty to
make available data underlying decision-making for all
drugs in its purview. We concur, and believe this approach
to be self-evident for any scientific body operating within
a political democracy as the EMA does not screen re-
quests by requiring a reason for accessing the data (but a
Fig. 1 Timeline of 12 requests along four milestone dates (initial request, initial decision, initial release of data, and final release of data). Data
points indicate, from left to right: initial request, initial decision, initial release of data, and final release of data
Table 3 Released documents
Request no. Request Pages Batches Pages per batch Redacted? Items missing? Request satisfied?
1 1 antiviral: oseltamivir 25,453 4 6363 No No Yes
2 2 vaccines: Pandemrix and Focetria 14,030 4 3508 Yes Yes Mostly
3 1 antipsychotic: aripiprazole 13,002 4 3251 Yes Not sure Yes
1 statin: atorvastatin
1 antidiabetic: pioglitazone
4 1 antiviral; oseltamivir 1897 3 632 Yes No Yes
5 1 antiviral: oseltamivir 14,208 5 2842 Yes Not sure Yes
6 1 antiviral: oseltamivir 318 1 318 Yes No No
7 13 antibioticsa 15,302 21 729 Yes No Yes
8 1 anti-inflammatory: adalimumab 20,793 12 1733 Yes Yes Mostly
9 1 antibiotic: bedaquiline 7315 10 732 Yes Yes Yes
10 48 medicines No release No
11 2 vaccines; Gardasil and Cervarix 6355 22 289 Yes Yes Yes
1 antiviral: sofosbuvir
12 1 volume expander: hydroxyethyl starch 8 1 8 Yes No Yes
aAltargo, Cayston, Colobreathe, Cubicin, Dificlif, Doribax, Invanz, Ketek, Tobi Podhaler, Trovan, Tygacil, Vibativ, Zinforo
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rationale for access when appealing a negative decision is
prudent).
We remain firm advocates of broader use of clinical
study reports but users should also be aware of EMA-
unrelated complexities in the most basic first step: iden-
tifying a trial. In some cases, a trial can have up to four
identifiers: two different alphanumeric identifiers given
by the manufacturer, a registry number and sometimes
an acronym. Because the EMA, the manufacturer and
registry operators do not necessarily provide tables of
holdings that cross-reference these IDs, this can be a
further source of confusion and resource wastage.
Over time, CSRs available under the EMA’s “reactive”
policy may become less important as they relate to pro-
gressively older pharmaceuticals and the EMA’s “pro-
spective” policy of publishing clinical trial data applies to
a greater number of drugs in current use. However, the
EMA’s reactive policy will remain of great interest for
the foreseeable future, especially should the prospective
policy falter.
Simple measures may at least partially address some of
the problems we identified. First, a permanent forum be-
tween the EMA and requestors may help each side
maximize the efficiency of the data request/release
process through mutual education and exchange of
views.
Second, a publicly available list of holdings by com-
pound name would focus requests and avoid unneces-
sary correspondence in identifying desired materials. On
several occasions the EMA offered us a list of its hold-
ings relating to our requests. These proved invaluable in
prioritizing and focusing our requests. Although these
lists were custom-created for our requests, publicly
available lists across EMA holdings would help clarify
requests up front and moderate expectations. One tan-
gible way to support the EMA’s efforts would be to call
for volunteer researchers to help build a list of EMA
holdings, perhaps in specific topic areas.
Third, release letters could be sent in the body of an
email instead of the current practice of email attach-
ments and web-based downloads. This would ensure
their searchability and ease of reading. Sections that are
generic to all letters should be reduced as much as pos-
sible and made visually distinct from the portions that
require the requestor’s attention.
Conclusions
The EMA is the only regulator in the world that is rou-
tinely releasing part of its holdings, but our experience
shows that document release can take considerable time
to occur and often only after a lengthy correspondence.
Despite the problems, the EMA’s unique efforts should
not be undermined. Independent researchers and users
should instead support the policy as at present it is the
most promising way to address reporting bias in litera-
ture. In this report, we have identified areas for improv-
ing the system. This case series details our experience
with the EMA, but we would like to hear from re-
searchers who approached industry.
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